HEPATIC FIBROSIS: MECHANISMS OF DEVELOPMENT AND TREATMENT ISSUES


Cite item

Full Text

Abstract

The review provides information on the main components and the localization of liver interstitial tissue, as well as the modern understanding of the mechanisms of formation, progression and regression of hepatic fibrosis. The role of stellate cells, hepatocytes and endothelial cells in maintaining the normal composition of the extracellular matrix of the liver is presented, as well as the role of these cells in the mechanisms of fibrosis in pathological conditions. Regulatory substances and mediators involved in the activation and transformation of stellate cells in myofibroblasts synthesizing collagen, which may be potential targets for antifibrotic therapy, are presented. Characteristics of repair processes in acute and chronic liver damage are demonstrated. Modern methods and new directions in the treatment of hepatic fibrosis are analyzed in details. The mechanisms of action and efficacy of standardized silymarin (Legalon) in the prevention and treatment of fibrosis in acute and chronic liver diseases are represented.

References

  1. Kuntz E, Kuntz HD. Hepatology, Textbook and Atlas. Verlag: Springer Medizin Verlag Heidelberg 2008.
  2. Bissel DM, Maher JJ. Hepatic fibrosis and cirrhosis. In: Zakim D, Boyer TD. (eds) Hepatology. A textbook of liver disease. 4th ed. Saunders Science (USA) 2003:395-416.
  3. Friedman SL. Cellular sources of collagen and regulation of collagen production in liver. Semin Liver Dis 1990;10:20-28.
  4. Albanis E, Friedman SL. Hepatic fibrosis: pathogenesis and principles of therapy. Clin Liver Dis 2001;5:315-34.
  5. Henderson NC, Iredale JP. Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci 2007;112:265-80.
  6. Okuno M, Moriwaki H, Imai S, et al. Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-beta in liver stellate cells. Hepatology 1997;26:913-16.
  7. Lee JM, Dedhar S, Kalluri R, et al. The epithelial-mesenchеmal transition: new insights in signaling, development and disease. J Cell Biol 2006;172:973-81.
  8. Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007;282:23337-347.
  9. Correll MD. Liver fibrosis: the hepatocyte revisited. Hepatology 2007;46:1659-60.
  10. Olaso E, Friedeman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol 1998;29:836-47.
  11. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104.
  12. Rojkind M, Dunn MA. Hepatic fibrosis. Gastroenterology 1979;76:849-54.
  13. Некрасова Т. П. Морфологическое исследование в оценке степени фиброза печени // Гепатологический форум, 2007. № 1. C. 11-13.
  14. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007;47:598-607.
  15. Poynard T. Hepatitis C and B. Management and treatment. 2nd ed. 2004.
  16. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis С. The Obsvirc, Metavir, Clinivir and Dosvirc groups. Lancet 1997;349:825-31.
  17. Fort J, Pilette C, Veal N, et al. Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. J Hepatol 1998;29:263-68.
  18. Lee DY, Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A and isosilybin B, isolated from Silybum marianum (milk thistle). J Nat Prod 2003;66:1171-74.
  19. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035-63.
  20. Вoigk G, Stroedter L, Herbst H, et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997;26:643-48.
  21. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008;135:1561-67.
  22. Rockey DC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005;3:95-107.
  23. Lieber CS, Leo MA, Cao Q, et all. Silymarin retards the progression of alcohol - induced hepatitis fibrosis in baboons. J Clin. Gastroenterol 2003;37:336-39.
  24. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9:105.
  25. Schuppan D, Strosser W, Burkard G, et al. Verminderung der Fibrosierungsaktivität durch Legalon® bei chronischen Lebererkrankungen. Z Allg Med 1998;74:577-84.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies